Q4: 2026-03-17 Earnings Summary
EPS of -$0.06 beats by $0.04
| Revenue of $0.00 beats by $0.00
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call March 17, 2026 4:30 PM EDT
Company Participants
Jennifer Good – Co-Founder, CEO, President, & Director
David Hastings – Chief Financial Officer & Principal Financial Officer
James Cassella – Chief Development Officer
Farrell Simon – Chief Commercial Officer
Conference Call Participants
Roanna Clarissa Ruiz – Leerink Partners LLC, Research Division
Judah Frommer – Morgan Stanley, Research Division
Jayed Momin – Stifel, Nicolaus & Company, Incorporated, Research Division
Alexa Deemer – Cantor Fitzgerald & Co., Research Division
Serge Belanger – Needham & Company, LLC, Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Brandon Folkes – H.C. Wainwright & Co, LLC, Research Division
Debanjana Chatterjee – JonesTrading Institutional Services, LLC, Research Division
William Wood – B. Riley Securities, Inc., Research Division
Presentation
Operator
Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2025 Earnings Conference Call.
[Operator Instructions]
Please be advised that today’s conference is being recorded.
Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company’s most recent annual report on Form 10-K, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference